Biostage, Inc. announced that it has received the anticipated formal response from the U.S. Food and Drug Administration related to the Company's Investigational New Drug (IND) application for the Cellspan Esophageal Implant. This anticipated letter, received December 26, details specific questions and clarifications that will enable Biostage to complete and submit its formal reply. Biostage received a preliminary communication from the FDA on November 27, allowing the Company to begin preparing its responses.